COMPANY

Cellectar Biosciences, Inc.

HQ: Florham Park, NJ source · cellectar.com ↗ · Mid-Atlantic

Keywords: oncology cancer tumors High-Grade Glioma macroglobulinemia Waldenstrom Macroglobulinemia Multiple Myeloma Hepatitis C triple-negative breast cancer Breast Cancer Pediatric Lymphoma Pediatric Brain Tumor DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcoma Osteosarcoma Waldenstrom Macroglobulinaemia Waldenstrom's Macroglobulinaemia Refractory Waldenstrom Macroglobulinemia With Nodal Disease Waldenstrom's Macroglobulinemia Recurrent Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Lymphoplasmacytic Lymphoma Marginal Zone Lymphoma Mantle Cell Lymphoma Diffuse Large B Cell Lymphoma Central Nervous System Lymphoma Non Small Cell Lung Cancer Glioblastoma Ovarian Cancer Glioma I-131-CLR1404 Iopofosine I 131 CLR 131 NOV-002 NOV-205 CLR 125 I-124-CLR1404

Location: Florham Park, NJ · source · Oct 14, 2026

Profile checked Oct 10, 2026

$146.9MRaised (2 yrs)14Trials (company is sponsor)8NIH grants

Timeline

2026-12 Trial start Phase 3: Evaluation of Iopofosine I 131 vs. R-CD in WM Patients source ↗
May 5, 2026 Raise Private placement: $140M (up to, as announced), announced May 5, 2026. Source: company's own press page. source ↗
Dec 5, 2025 Trial start 1: Phase 1 Study of CLR 125 in Triple Negative Breast Cancer source ↗
Jul 2, 2025 Raise Follow-on offering: $6.9M (total, as published), announced Jul 2, 2025. Source: company's own press page. source ↗
Oct 1, 2023 Trial start Phase 1: Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG source ↗
Apr 30, 2019 Trial start Phase 1: Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas source ↗
Jul 26, 2017 Trial start Phase 2: Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom source ↗
2015-02 Trial start Phase 1: Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma source ↗
2014-05 Trial start Phase 2: Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma source ↗
2014-02 Trial start Phase 2: Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma source ↗
2011-12 Trial start Phase 1: Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned source ↗
2010-03 Trial start Phase 2: A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy source ↗
2009-06 Trial start Phase 1: Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors source ↗
2006-11 Trial start Phase 3: Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer source ↗
2006-08 Trial start Phase 1: Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy source ↗
2006-07 Trial start Phase 2: Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer source ↗

Upcoming milestones

Jun 30, 2027 (ESTIMATED) · Phase 1 · Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG · NCT05610891
Jun 30, 2027 (ESTIMATED) · Phase 1 · Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas · NCT03478462
2028-02 (ESTIMATED) · 1 · Phase 1 Study of CLR 125 in Triple Negative Breast Cancer · NCT07311993
2032-01 (ESTIMATED) · Phase 3 · Evaluation of Iopofosine I 131 vs. R-CD in WM Patients · NCT07766421

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $146.9M. Last 2 years.

May 5, 2026 Private placement: $140M (up to, as announced), announced May 5, 2026. Source: company's own press page. source ↗
Jul 2, 2025 Follow-on offering: $6.9M (total, as published), announced Jul 2, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 14

Record	Title	Phase	Status	Start	Primary completion
NCT07311993	Phase 1 Study of CLR 125 in Triple Negative Breast Cancer	1	Recruiting	Dec 5, 2025	2028-02 (estimated)
NCT05610891	Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG	Phase 1	Active, not recruiting	Oct 1, 2023	Jun 30, 2027 (estimated)
NCT03478462	Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas	Phase 1	Active, not recruiting	Apr 30, 2019	Jun 30, 2027 (estimated)
NCT07766421	Evaluation of Iopofosine I 131 vs. R-CD in WM Patients	Phase 3	Not yet recruiting	2026-12	2032-01 (estimated)
NCT02952508	Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom	Phase 2	Active, not recruiting	Jul 26, 2017	Jun 22, 2026 (estimated)
NCT02278315	Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma	Phase 1	Completed	2015-02	Dec 9, 2020 (actual)
NCT00347412	Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer	Phase 3	Completed	2006-11	2010-01 (actual)
NCT01058512	A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy	Phase 2	Completed	2010-03	2010-12 (actual)
NCT01898273	Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma	Phase 2	Terminated	2014-02	2015-09 (estimated)
NCT00345540	Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer	Phase 2	Completed	2006-07	2008-05 (actual)
NCT01495663	Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned	Phase 1	Completed	2011-12	2013-11 (actual)
NCT01778088	Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma	Phase 2	Withdrawn	2014-05	2014-06 (estimated)
NCT00925275	Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors	Phase 1	Completed	2009-06	2010-02 (actual)
NCT00372983	Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy	Phase 1	Completed	2006-08	Not listed

NIH awards 8

Annual award amounts. Total $6.4M.

Aug 30, 2023 NIH award 5R44CA265558-03 FY2023: $475,806 awarded for that fiscal year; activity R44 (SBIR); PI LONGCOR, JARROD; recipient as written: CELLECTAR BIOSCIENCES, INC., Florham Park, NJ. An Open-Label, Multicenter, Phase source ↗
Aug 18, 2023 NIH award 5R44CA272070-02 FY2023: $965,201 awarded for that fiscal year; activity R44 (SBIR); PI REILLY, LAURENCE; recipient as written: CELLECTAR BIOSCIENCES, INC., Florham Park, NJ. A Phase 1b, Open-Label, Study of source ↗
Sep 16, 2022 NIH award 1R44CA272070-01A1 FY2022: $1,034,797 awarded for that fiscal year; activity R44 (SBIR); PI REILLY, LAURENCE; recipient as written: CELLECTAR BIOSCIENCES, INC., Florham Park, NJ. A Phase 1b, Open-Label, Stud source ↗
Aug 31, 2022 NIH award 5R44CA265558-02 FY2022: $755,603 awarded for that fiscal year; activity R44 (SBIR); PI LONGCOR, JARROD; recipient as written: CELLECTAR BIOSCIENCES, INC., Florham Park, NJ. An Open-Label, Multicenter, Phase source ↗
Aug 28, 2021 NIH award 1R44CA265558-01 FY2021: $763,080 awarded for that fiscal year; activity R44 (SBIR); PI LONGCOR, JARROD; recipient as written: CELLECTAR BIOSCIENCES, INC., Florham Park, NJ. An Open-Label, Multicenter, Phase source ↗
2016 NIH contract (government contract; not a grant and not an investment round) 261201500071C-3-0-1 FY2016: $1,999,370 awarded for that fiscal year; activity N43 (OTHER_NIH); PI TITZ, BENJAMIN; recipient as written: CELLECTAR BIOSCIENCES, INC., Florham Park, NJ. I source ↗
2015 NIH contract (government contract; not a grant and not an investment round) 261201500071C-0-0-1 FY2015: $292,715 awarded for that fiscal year; activity N43 (OTHER_NIH); PI TITZ, BENJAMIN; recipient as written: CELLECTAR BIOSCIENCES, INC., Florham Park, NJ. IGF source ↗
Sep 22, 2007 NIH award 1R41CA117259-01A2 FY2007: $150,247 awarded for that fiscal year; activity R41 (STTR); PI TEW, KENNETH D.; recipient as written: CELLECTAR BIOSCIENCES, INC., NEWTON, MA. PRECLINICAL DEVELOPMENT OF A GLUTATHI source ↗